Caspase-1 (CASP1)
CASP1 encodes caspase-1, a cysteine protease best known for its central role in inflammasome signaling and pyroptotic cell death.
CASP1 encodes caspase-1, a cysteine protease best known for its central role in inflammasome signaling and pyroptotic cell death. In canonical innate immune pathways, caspase-1 is activated downstream of inflammasome complexes such as NLRP3, where it processes the pro-forms of interleukin-1 beta (IL-1β) and IL-18 into their mature, bioactive cytokines and can also cleave Gasdermin D (GSDMD) to drive membrane pore formation and pyroptosis. Through these functions, CASP1 links pathogen sensing, sterile inflammation, and tissue injury responses.
Because of this position in inflammatory signaling, CASP1 is frequently studied in diseases characterized by excessive inflammasome activation, including neuroinflammation, inflammatory bowel disease, rheumatoid arthritis, ischemia-reperfusion injury, cancer-associated inflammatory cell death, and degenerative disorders. In recent work, CASP1 has also been examined as a therapeutic target in combination with pathways involving toll like receptor 4 (TLR4), NF-κB, TXNIP/NLRP3, mitophagy, and Sirt1/HIF-1α, as well as with compounds such as sulforaphane, kaempferol, quercetin, apigenin, salidroside, emodin, and amygdalin.
Where the papers sit
9 papers from the last 6 months study Caspase-1 (CASP1) directly · updated from PubMed 15 Nov 2026
Study type 0 clinical trials · 7 preclinical · 2 unclassified
Themes one subject
Those 9 are all about one subject.
-
Inflammation-Related Disease Mechanisms
CASP1 recurs as a marker or mediator of inflammatory injury, regulated cell death, and tissue dysfunction across diverse diseases. The work spans liver toxicity and disease, neuroinflammation, atherosclerosis, cancer immune evasion, ischemic injury, and degenerative disorders. Network pharmacology and experimental validation are commonly paired to connect candidate compounds or genes with CASP1-related pathways. The shared focus is inflammatory and cell-death biology rather than one disease, drug, or treatment strategy.
Papers
The 9 papers from the last 6 months that study Caspase-1 (CASP1) directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Inflammation-Related Disease Mechanisms (9)
- Bellidifolin alleviates doxorubicin-induced hepatotoxicity: a study integrating network pharmacology, molecular docking, and experimental validation. Die Naturwissenschaften · 22 Sept 2026 PMID 42771163
- Activating a novel cell death pathway to target PI-resistant multiple myeloma and enhance immunogenic cell death. Apoptosis : an international journal on programmed cell death · 7 Sept 2026 PMID 42704369
- Anti-neuroinflammatory and neuroprotective effects of sweroside and swertiamarin from Swertia bimaculata in an in vitro microglial activation model. Biochemical and biophysical research communications · 31 Aug 2026 PMID 42673911
- CASP1 as a key autophagy-related gene in atherosclerosis: Identification by bioinformatics analysis and experimental validation. PloS one · 19 Aug 2026 PMID 42616740
- Splicing-mediated control of hnRNPD isoform switching by SRSF2 drives PD-L1-dependent immune evasion in gallbladder cancer. Oncogene · 20 Jul 2026 PMID 42477458
- Non-absorbable antibiotics worsen alcohol-associated liver disease in gastric acid-suppressed mice. Gut microbes · 9 Jul 2026 PMID 42421214
- Molecular mechanism of hydromorphone preconditioning in cerebral ischemia/reperfusion‑induced inflammatory injury. International journal of molecular medicine · 19 Jun 2026 PMID 42318970
- Irbesartan ameliorates high‑glucose‑induced epithelial‑mesenchymal transition by downregulating the expression of NLRP3 in HK‑2 cells. Molecular medicine reports · 19 Jun 2026 PMID 42318962
- Identification of potential targets of kaempferol for the treatment of intervertebral disc degeneration based on network pharmacology and multi-omics analysis. Naunyn-Schmiedeberg's archives of pharmacology · 12 Jun 2026 PMID 42283840
By study type
Preclinical: animal, cell and lab studies (7)
- Bellidifolin alleviates doxorubicin-induced hepatotoxicity: a study integrating network pharmacology, molecular docking, and experimental validation. Die Naturwissenschaften · 22 Sept 2026 PMID 42771163
- Activating a novel cell death pathway to target PI-resistant multiple myeloma and enhance immunogenic cell death. Apoptosis : an international journal on programmed cell death · 7 Sept 2026 PMID 42704369
- Anti-neuroinflammatory and neuroprotective effects of sweroside and swertiamarin from Swertia bimaculata in an in vitro microglial activation model. Biochemical and biophysical research communications · 31 Aug 2026 PMID 42673911
- CASP1 as a key autophagy-related gene in atherosclerosis: Identification by bioinformatics analysis and experimental validation. PloS one · 19 Aug 2026 PMID 42616740
- Non-absorbable antibiotics worsen alcohol-associated liver disease in gastric acid-suppressed mice. Gut microbes · 9 Jul 2026 PMID 42421214
- Molecular mechanism of hydromorphone preconditioning in cerebral ischemia/reperfusion‑induced inflammatory injury. International journal of molecular medicine · 19 Jun 2026 PMID 42318970
- Irbesartan ameliorates high‑glucose‑induced epithelial‑mesenchymal transition by downregulating the expression of NLRP3 in HK‑2 cells. Molecular medicine reports · 19 Jun 2026 PMID 42318962
Unclassified: not yet indexed with MeSH (2)
- Splicing-mediated control of hnRNPD isoform switching by SRSF2 drives PD-L1-dependent immune evasion in gallbladder cancer. Oncogene · 20 Jul 2026 PMID 42477458
- Identification of potential targets of kaempferol for the treatment of intervertebral disc degeneration based on network pharmacology and multi-omics analysis. Naunyn-Schmiedeberg's archives of pharmacology · 12 Jun 2026 PMID 42283840
Written from 9 PubMed abstracts, each one listed by PMID above. Published: 2026-06-16. Last written: 2026-09-24 by GPT. Drafted by language models from published abstracts; not medical advice.